HER2 antibody composition
A composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
1. A method of treating HER2-expressing cancer in a patient comprising administering a pharmaceutical formulation to the patient in an amount effective to treat the cancer, wherein the formulation comprises a composition comprising: (a) a main species HER2 antibody that binds to domain II of HER2 and comprises the variable light amino acid sequence in SEQ ID No. 3 and the variable heavy amino acid sequence in SEQ ID No. 4, and (b) the main species HER2 antibody comprising an amino-terminal leader extension, wherein the amino-terminal leader extension comprises VHS-, wherein from 5% to about 15% of the antibody molecules in the composition comprise the amino-terminal leader extension, as quantified by cation exchange analysis in a pharmaceutically acceptable carrier.
2. A method of treating HER2-expressing cancer in a patient comprising administering a pharmaceutical formulation to the patient in an amount effective to treat the cancer, wherein the formulation comprises a composition comprising: (a) a main species HER2 antibody comprising the variable light sequence in SEQ ID No. 3 and the variable heavy sequence in SEQ ID No. 4, and (b) the main species antibody comprising a VHS-amino-terminal leader extension attached to one or two variable light domains thereof, wherein from 5% to about 20% of antibody molecules in the composition comprise the VHS-amino-terminal leader extension in a pharmaceutically acceptable carrier.